3,5-dihydroxyphenylglycine has been researched along with Dementia Praecox in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Barry, RL; Byun, NE; Conn, PJ; Gore, JC; Joffe, ME; Li, B; Lindsley, CW; Luessen, DJ; Maksymetz, J; Niswender, CM | 1 |
Blobaum, AL; Byers, FW; Cho, HP; Conn, PJ; Garcia-Barrantes, PM; Lindsley, CW; Locuson, CW; Niswender, CM; Rook, JM; Xiang, Z | 1 |
2 other study(ies) available for 3,5-dihydroxyphenylglycine and Dementia Praecox
Article | Year |
---|---|
mGlu
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Cognitive Dysfunction; Disease Models, Animal; Excitatory Amino Acid Agonists; Female; GABAergic Neurons; Glycine; Interneurons; Male; Memory, Short-Term; Mice, Inbred C57BL; Mice, Transgenic; Neural Inhibition; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Resorcinols; Schizophrenia; Schizophrenic Psychology; Somatostatin | 2021 |
Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and M
Topics: Animals; Central Nervous System; Epilepsy; GABA Agonists; GABA Modulators; Half-Life; Humans; Molecular Conformation; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Schizophrenia; Structure-Activity Relationship | 2015 |